ICMJE DISCLOSURE FORM

Date: 1/11/2022

Your Name: Mark Edward Holland

Manuscript Title: An evidence synthesis and cost-effectiveness study of Venous ThromboEmbolism risk Assessment Models for hospital inpatients: the VTEAM project

Manuscript Number (if known): Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	**Specifications/Comments (e.g., if payments were made to you or to your institution)**
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.**	☐ None	
		NIHR funded study	I received no direct payments. The hospital where I worked at the time this study started, Salford Royal NHS Foundation Trust were paid but this did not come to me. I left the hospital on 30/9/20 and worked voluntarily on this project.
			Click the tab key to add additional rows.
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ **None**	
3	Royalties or licenses	☒ **None**	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ **None**	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☐ **None**	
		In May 2021 I completed an online study package for Doctors.Net. However, this was not related to this study or this topic; it was about the initial care of the unconscious patient. Prior to the COVID-19 pandemic, I was a regular speaker for the BMJ at their Masterclass series, on the subject of older people. In 2017 I gave a talk at medical CPD update meeting called ReValiaid on the subject of deep vein thrombosis diagnosis and management.	All paid to me
		November 2016 – I gave a talk sponsored by Pfizer/BMS on the management of deep vein thrombosis BMS= Bristol Myers Squibb	Paid to me
		February 2017 – I gave a talk sponsored by Pfizer/BMS on the management of deep vein thrombosis	Paid to me
6	Payment for expert testimony	☒ **None**	
		In 2019 I completed two legal reports for Hill Dickinson Solicitors. Neither was related to the subject of this study. In 2018 a legal case concluded that I been involved with 5 years. It was about a patient in AF who had a stroke. However, there was no direct relevance to this study, although it did involve discussion about anticoagulation, although this preceded the widespread use of direct oral anticoagulants.	Fees paid to me
7	Support for attending meetings and/or travel	☐ **None**	
		In June 2019 I attended the Welsh Acute Physicians meeting in South Wales. At this meeting was a mini-symposium run by Pfizer/BMS regarding the use of direct oral anticoagulants.	Refreshments at the symposium comprised a seat down meal in a private room in a restaurant.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
8	Patents planned, issued or pending	☒ **None**	
9	Participation on a Data Safety Monitoring Board or Advisory Board	☒ **None**	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☐ **None**	
		From 2012 to 2015 I was the chair of a group who wrote a pan-Manchester deep vein thrombosis care guideline. The guideline was commissioned by what was commissioned by a Manchester NHS body.	I was paid 1PA (4 hours per week) for 6 months. The money went to my trust and was used for our ward training fund.
11	Stock or stock options	☒ **None**	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ **None**	
13	Other financial or non-financial interests	☐ **None**	
		I am also a patient who has previously had a pulmonary embolism (2013) and have made the choice to take life-long warfarin. I make this statement to show that I clearly personally have no bias towards using direct oral anticoagulants.	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.